Pulse Biosciences (NASDAQ:PLSE) Posts Earnings Results, Beats Expectations By $0.06 EPS

Pulse Biosciences (NASDAQ:PLSE) released its quarterly earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06, FiscalAI reports. The firm had revenue of ($0.09) million for the quarter, compared to analysts’ expectations of $0.23 million.

Here are the key takeaways from Pulse Biosciences’ conference call:

• Company secured IDE approvals for both the nPulse cardiac catheter and the nPulse cardiac clamp and expects to commence and complete pivotal enrollment in 2026, supported by European feasibility data showing 100% procedural success at six months, 96% at one year, and 90% freedom from AF at 12 months.
• The Vibrance soft-tissue rollout remains a tightly controlled market-development launch with Q4 revenue of $264,000; PRECISE benign thyroid nodule enrollment should complete in the next few months and expand to 100 patients to support reimbursement and regulatory filings.
• Cash ended 2025 at $80.7 million with Q4 operating cash use of $14.8 million and widening non-GAAP losses, and the company filed a $200 million shelf registration—signaling potential need for future capital and dilution risk.
• Pulse materially strengthened its intellectual property and partnerships—adding 67 issued and 77 pending patents in 2025 (totaling 250 granted and 180 pending) while pursuing mapping integrations and an MD Anderson collaboration to accelerate commercial and oncologic applications.

Pulse Biosciences Price Performance

Shares of Pulse Biosciences stock opened at $24.34 on Friday. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -21.54 and a beta of 1.77. The business has a 50-day moving average of $16.21 and a 200 day moving average of $16.03. Pulse Biosciences has a 12 month low of $12.56 and a 12 month high of $26.30.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Mizuho set a $30.00 price objective on Pulse Biosciences in a research report on Friday, February 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $26.00.

Insider Activity

In other news, insider Kevin Patrick Danahy sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $23.63, for a total value of $472,600.00. Following the completion of the transaction, the insider owned 43,298 shares of the company’s stock, valued at approximately $1,023,131.74. This trade represents a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 80,000 shares of company stock worth $1,876,200 over the last 90 days. 74.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pulse Biosciences

Several institutional investors have recently modified their holdings of the business. Portolan Capital Management LLC purchased a new stake in shares of Pulse Biosciences during the third quarter worth $1,809,000. Brooklyn Investment Group grew its stake in Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock worth $1,844,000 after purchasing an additional 100,081 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in Pulse Biosciences during the 4th quarter worth about $382,000. UBS Group AG increased its holdings in Pulse Biosciences by 53.4% during the 3rd quarter. UBS Group AG now owns 76,856 shares of the company’s stock worth $1,360,000 after purchasing an additional 26,739 shares during the period. Finally, State Street Corp raised its position in Pulse Biosciences by 6.0% in the 4th quarter. State Street Corp now owns 447,067 shares of the company’s stock valued at $6,138,000 after purchasing an additional 25,187 shares in the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.